Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Lymphoid 1Gastrointestinal 1Endocrine 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma, Alveolar 1Lymphoma 1

Interventions

Temozolomide 63Cyclophosphamide 55Radiotherapy 53Bevacizumab 50Doxorubicin 48Ifosfamide 33pazopanib 28fludarabine phosphate 28Etoposide 27Radiation 24Gemcitabine 24pembrolizumab 23Sirolimus 23Sunitinib 22Filgrastim 22Irinotecan 21Whole-Body Irradiation 20Peripheral Blood Stem Cell Transplantation 20Mycophenolic Acid 20Imatinib Mesylate 20Vincristine 19Magnetic Resonance Spectroscopy 18Sorafenib 16Methotrexate 16Busulfan 16Melphalan 15Carboplatin 15Docetaxel 14Cyclosporine 14temsirolimus 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × BAY 1895344 × Sarcoma × Clear all
NCT05071209 2026-01-23

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
31 enrolled 14 charts
LymphoidSarcoma

Lymphoma, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡